USPTO serial 88081099
Reviewed by CopyMark Law Group
Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
CHICAGO, IL
Chicago, IL
Chicago, IL
Chicago, IL
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rebecca E. Coleman
Rebecca E. Coleman BrownWinick Law Firm666 Grand Ave., Suite 2000Des Moines, IA 50309United States| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Assays for research purposes; Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; Diagnostic reagents for scientific or research use; Diagnostic reagents for scientific use; Reagents for research purposes; Reagents for scientific and research use; Reagents for scientific or medical research use; Reagents for use in scientific apparatus for chemical or biological analysis | ACTIVE | Jun 19, 2018 |
| 005 | Diagnostic biomarker reagents for medical purposes; Medical diagnostic reagents and assays for testing of body fluids | ACTIVE | Jun 19, 2018 |
| 035 | Providing business intelligence services in the fields of medical devices, pharmaceuticals and the life sciences | ACTIVE | Jun 19, 2018 |
| 042 | Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Custom design and development of chemical reagents and biochemical assays; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical products development; Pharmaceutical research and development; Pharmaceutical research services; Providing reagent sample testing and diagnostic services for others in the fields of science and research related thereto; Research and development in the pharmaceutical and biotechnology fields | ACTIVE | Jun 19, 2018 |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| May 7, 2025 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| May 5, 2025 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| May 5, 2025 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| May 1, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 16, 2025 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jan 15, 2025 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Dec 4, 2024 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Dec 4, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 4, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 4, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 16, 2024 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Apr 16, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 29, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 29, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 9, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 26, 2018 | ALIE | ASSIGNED TO LIE | — |
| Dec 19, 2018 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 5, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 5, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 5, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 5, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 5, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 3, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 25, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 20, 2018 | NWAP | NEW APPLICATION ENTERED | — |